Article Correctness Is Author's Responsibility: Role of PCSK9 inhibitors in high risk patients with dyslipidemia

(Bentham Science Publishers) The purpose of this review is to present available data on the efficacy and safety of the two available PCSK9 inhibitors in patients with FH, and importantly to discuss potential differences between the two drugs.A comprehensive literature search was performed to identify available data from clinical studies evaluating the impact of evolocumab or alirocumab on lipid and CV parameters in patients with FH.